ANDA 207957, held by Hikma. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 207957 (Fluticasone Propionate), held by Hikma, was first approved by FDA on May 26, 2016, with 3 approved supplements and 0 published complete response letters.
Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 26, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluticasone Propionate0.05MG/SPRAY · spray, metered;nasal | Fluticasone Propionate | OTC |
| Nov 27, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 29, 2016 | Supplement 2Manufacturing | Approved | None posted |
| Aug 2, 2016 | Supplement 1Manufacturing | Approved | None posted |
| May 26, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters